Table 3.

Bivariable Associations of 6 Month Physical Measures with 12 Month Patient-Centered Outcomes

6 Month Physical Measures	Alive between 6 and 12m^a	No Hospitalization between 6 and 12m^b	Alive at Home at 12m^c	SF-36 PCS 12m	EQ-5D Utility 12m
	OR (95% CI)	OR (95% CI)	OR (95% CI)	Pearson r (95% CI)	Pearson r (95% CI)
Body Structure and Function Measures
FEV1, each 10% predicted
Combined Sample	1.11 (0.79,1.55)	1.08 (0.92,1.28)	1.00 (0.78,1.28)	0.18 (0.05,0.31)^**	0.02 (−0.11,0.15)
ICAP	1.78 (1.05,3.04)^*	0.84 (0.63,1.12)	1.72 (1.10,2.71)^*	0.12 (−0.09,0.32)	−0.09 (−0.29,0.12)
ALTOS	0.68 (0.39,1.20)	1.27 (1.01,1.59)^*	0.75 (0.53,1.06)	0.22 (0.04,0.38)^*	0.11 (−0.07,0.28)
Arm muscle area, each 10%
Combined Sample	1.04 (0.70,1.54)	0.93 (0.76,1.14)	1.12 (0.86,1.45)	0.08 (−0.05,0.22)	0.09 (−0.05,0.22)
ICAP	0.64 (0.25,1.60)	0.87 (0.59,1.30)	0.53 (0.24,1.20)	0.24 (0.03,0.42)^*	0.17 (−0.04,0.36)
ALTOS	1.20 (0.79,1.82)	0.98 (0.77,1.24)	1.22 (0.93,1.60)	0.03 (−0.15,0.20)	0.03 (−0.15,0.20)
MIP, each 10% predicted
Combined Sample	1.21 (0.96,1.51)	1.04 (0.94,1.14)	1.09 (0.94,1.26)	0.15 (0.02,0.28)^*	0.03 (−0.10,0.17)
ICAP	1.31 (0.89,1.93)	1.03 (0.90,1.18)	1.12 (0.86,1.45)	0.01 (−0.19,0.22)	−0.18 (−0.37,0.03)
ALTOS	1.15 (0.85,1.54)	1.04 (0.90,1.19)	1.09 (0.91,1.32)	0.25 (0.07,0.41)^**	0.20 (0.02,0.36)^*
MMT, each 10% of maximum MRC score
Combined Sample	0.97 (0.41,2.28)	1.21 (0.81,1.82)	1.44 (0.86,2.43)	0.32 (0.19,0.43)^**	0.23 (0.10,0.36)^**
ICAP	1.33 (0.48,3.70)	1.04 (0.57,1.90)	1.23 (0.51,2.95)	0.34 (0.14,0.51)^**	0.03 (−0.18,0.23)
ALTOS	0.59 (0.13,2.67)	1.39 (0.80,2.40)	1.69 (0.85,3.36)	0.31 (0.14,0.46)^**	0.41 (0.25,0.54)^**
Grip strength, each 10% predicted
Combined Sample	0.90 (0.70,1.16)	1.08 (0.95,1.24)	0.98 (0.82,1.19)	0.08 (−0.05,0.21)	0.05 (−0.09,0.18)
ICAP	0.97 (0.65,1.44)	1.17 (0.94,1.46)	0.97 (0.69,1.35)	0.08 (−0.13,0.28)	−0.10 (−0.30,0.11)
ALTOS	0.86 (0.62,1.19)	1.03 (0.87,1.22)	0.99 (0.79,1.24)	0.09 (−0.09,0.26)	0.13 (−0.05,0.30)
Activity Measures
6MWT, each 10% predicted
Combined Sample	1.16 (0.84,1.59)	1.27 (1.08,1.50)^**	1.13 (0.90,1.41)	0.42 (0.30,0.53)^**	0.23 (0.10,0.35)^**
ICAP	1.21 (0.76,1.91)	1.20 (0.94,1.54)	1.14 (0.77,1.67)	0.43 (0.24,0.58)^**	0.22 (0.02,0.41)^*
ALTOS	1.12 (0.71,1.75)	1.32 (1.05,1.67)^*	1.17 (0.88,1.56)	0.44 (0.28,0.57)^**	0.28 (0.11,0.44)^**
4-m gait speed, each 0.11 m/sec (ALTOS only)	0.91 (0.71,1.17)	1.29 (1.06,1.58)^*	1.01 (0.82,1.24)	0.42 (0.27,0.56)^**	0.34 (0.17,0.48)^**
Participation Measures
Number of ADL dependencies (ICAP only)	0.67 (0.35,1.29)	0.90 (0.52,1.53)	0.76 (0.39,1.45)	0.01 (−0.19,0.22)	0.00 (−0.21,0.20)
Number of IADL dependencies (ICAP only)	0.55 (0.34,0.91)^*	1.13 (0.87,1.47)	0.69 (0.49,0.98)^*	−0.38 (−0.54,−0.18)^**	−0.29 (−0.47,−0.09)^**
FPI-Total, per 0.20 unit^‡ (ALTOS only)	0.96 (0.71,1.30)	1.14 (0.99,1.32)	1.16 (0.96,1.39)	0.50 (0.36,0.62)^**	0.42 (0.26,0.55)^**

Abbreviations: FEV1: forced expiratory volume in 1 second; MIP: maximal inspiratory pressure; MMT: manual muscle testing; MRC: Medical Research Council; 6MWT: six minute walk test; 4-m: 4-meter; m/sec: meter per second; ADL: activities of daily living; IADL: instrumental activities of daily living; FPI: Functional Performance Inventory; SF-36 PCS: Medical Outcomes Short-Form 36 Physical Component Score; EQ-5D: Euro-QOL.

p<0.05;

^**

p<0.01;

OR = Odds Ratio;

Alive between 6 and 12m (Yes=1, No=0, Combined: 1, n=224, 96%; 0, n=9, 4%; ICAP: 1, n=95, 96%; 0, n=4, 4%; ALTOS:1, n=129, 96%; 0, n=5, 4%);

No Hospitalization between 6 and 12m (Yes=1, No=0, Combined: 1, n=157, 76%; 0, n=49, 24%; ICAP: 1, n=59, 73%; 0, n=22, 27%; ALTOS: 1, n=98, 78%; 0, n=27, 22%);

Alive at home outcome for 12m (Yes=1, No=0; Combined: 1, n=208, 92%, 0, n=19, 8%; ICAP: 1, n=88, 94%, 0, n=6, 6%; ALTOS: 1, n=120, 90%; 0, n=13, 10%);

^†

0.11 m/sec is an estimated MCID for the 4-m gait speed test based on prior study among COPD patients (Reference: Kon et al. Eur Respir J. 2014;43(5):129881305);

^‡

0.20 is an estimated MCID for the Functional Performance Inventory